Save

FULL TITLE

A new treatment for pre-eclampsia. 

OVERVIEW

Proof-of-Concept Trial on Selective Removal of the Antiangiogenic Factor Soluble Fms-like Tyrosine Kinase-1 (sFlt-1) in Pregnant Women with Preeclampsia via Apheresis Utilizing the Flt-1 Adsorption Column.

WHO CAN PARTICIPATE IN THIS STUDY? 

Pregnant women with pre-eclampsia before 32 weeks gestation

ABOUT THE STUDY 

Pre-eclampsia is a potentially serious condition that can put the health and wellbeing of the mother and the baby at risk. There are no effective treatments for pre-eclampsia, except to get the baby out (delivery). However, premature birth can lead to health problems for the baby. Babies born very prematurely may not be able to survive. Now, a clinical trial is being carried out to test whether a new medical device could effectively and safely treat pre-eclampsia.

Abnormally high levels of a protein called sFIt-1 can be found in the blood of pregnant women with pre-eclampsia. This protein is thought to cause many of the problems that occur with pre-eclampsia. The new treatment uses an approach called apheresis to reduce the level of the sFlt-1 protein in the mother’s blood. This is done by circulating the mother’s blood through a machine, using a filter to remove the protein before returning blood to the mother. In some ways, this is similar to the dialysis treatment kidney patients receive.

ETHICAL APPROVAL 

REC reference 16/SC/0200

CONTACT US TO GET INVOLVED 

If you are interested in taking part, you can use our contact form, or  call 01865 572258 or email osprea@wrh.ox.ac.uk